Welcome to our dedicated page for TRxADE HEALTH news (Ticker: MEDS), a resource for investors and traders seeking the latest updates and insights on TRxADE HEALTH stock.
TRxADE Health, Inc. (NASDAQ: MEDS) is a pioneering health service IT company based in the United States, dedicated to revolutionizing the retail pharmacy experience. Through its innovative platform trxade.com, the company provides a comprehensive web-based pharmaceutical purchasing and analytics system. This platform allows licensed pharmaceutical buyers, including pharmacies, long-term care facilities, hospitals, and physicians, to shop, compare products, and pricing from pharmaceutical suppliers nationwide. TRxADE’s platform enhances supplier competition, driving down costs for buyers while offering a secure and easy-to-manage location for all purchase activities.
TRxADE’s portfolio encompasses various products and services such as Integra Pharma Solutions, LLC, Community Specialty Pharmacy, LLC, Delivmeds.com, and the Bonum Health Hub and Application. The company's business segments include TRxADE, Inc., Superlatus, LLC, Integra Pharma, LLC, among others, with the majority of its revenue coming from TRxADE, Inc.
In recent developments, TRxADE Health has merged with Superlatus, Inc., a leading food technology and distribution company. This merger includes a binding agreement to acquire The Urgent Company Inc. and its popular consumer brands such as Coolhaus, Brave Robot, Modern Kitchen, and California Performance Co.. The acquisition aims to elevate TRxADE Health's position in sustainable and fair food products, facilitating entry into new markets and increasing market share. Superlatus is set to introduce innovative snack products like pulse-based twisted protein snacks through its Brave Robot brand, leveraging advanced food extrusion technology developed by Sapientia Technology, LLC.
These strategic moves align with TRxADE Health’s vision of expanding its market presence and fostering growth. The acquired consumer brands are already available in over 6,000 retail stores across the nation, including Whole Foods, Thrive Market, Kroger, and Costco, among others. The company’s commitment to enhancing the retail pharmacy and food technology sectors underscores its significant role in these industries.
For more information, visit TRxADE Health, Inc..
TRxADE Health, Inc. (NASDAQ: MEDS) has announced a significant corporate change. The company, along with its wholly owned subsidiary Scienture, , will be rebranding as Scienture Holdings, Inc. effective Monday, September 23, 2024. This transformation extends to the stock market, where the company will begin trading under the new ticker symbol NASDAQ:SCNX on the same date.
This name change represents a strategic shift for the company, potentially aligning its corporate identity more closely with its subsidiary's operations. The move could signal a new direction or focus for the business, though specific reasons for the change were not provided in the announcement.
TRxADE Health (NASDAQ: MEDS) has announced changes to the executive leadership team of its subsidiary, Scienture. Narasimhan Mani, Ph.D., MBA has been appointed as Scienture's President, bringing over 25 years of experience in the pharmaceutical industry. Shankar Hariharan, Ph.D., the current President and CEO, will remain as CEO. Rahul Surana, Ph.D., MBA has been promoted to Executive VP and COO.
Dr. Mani's extensive experience includes roles at New Rhein Healthcare Investors, Kesin Pharma, Xiromed , and Amneal Pharmaceuticals. Dr. Hariharan, the founder of Scienture, has over 37 years of experience in the pharmaceutical industry, having held leadership positions at Forest Labs, Par Pharmaceuticals, and Amneal Pharmaceuticals. These leadership changes aim to expand capabilities and drive growth as Scienture prepares for upcoming specialty portfolio launches.
TRxADE Health, Inc. (Nasdaq: MEDS) and Scienture, Inc. have announced the closing of their business combination in an all-stock transaction valued at $103 million. TRxADE acquired all of Scienture's assets in exchange for shares of TRxADE stock, including common stock and non-voting convertible preferred stock. The combined company, to be renamed Scienture Holdings, Inc., will focus on bringing innovative branded and specialty pharmaceutical products to market.
The merger aims to enhance patient care and add value to the healthcare system. Scienture's portfolio is supported by an experienced leadership team with expertise in various aspects of pharmaceutical development and commercialization. The company's patient-centric approach targets a wide range of therapeutic areas, with a commitment to improving health outcomes for patients, physicians, and other healthcare stakeholders.
TRxADE Health has declared a special cash dividend of $1.50 per share. This dividend will be paid to shareholders of record as of July 19, 2024, and distributed around July 24, 2024. The funds for this dividend stem from the proceeds of the asset sale of the Company’s web-based market platform in May 2024.
TRxADE Health has announced the filing of its Q1 2024 10-Q report, demonstrating compliance with Nasdaq listing rules and reporting a net income of over $21 million. This significant profit stems from the sale of nearly all assets of its subsidiary, Trxade, Inc., to Micro Merchant Systems, Inc. for $22.66 million. An additional payment of $7.5 million was received in May 2024. The company had previously received a notice of noncompliance from Nasdaq due to a delay in filing the report, but believes it has now rectified the issue.
On May 23, 2024, TRxADE Health received a notice from the Nasdaq Listing Qualifications Department regarding a late filing of its Quarterly Report on Form 10-Q for the period ending March 31, 2024. This notice indicates non-compliance with Nasdaq Listing Rule 5250(c)(1), which mandates timely filing of periodic reports. The company must present a compliance plan by July 22, 2024. If accepted, Nasdaq might grant an extension until November 18, 2024, to regain compliance. This notice does not immediately affect the listing or trading of TRxADE Health's stock. The company is working to file the Form 10-Q as soon as possible.
FAQ
What is the current stock price of TRxADE HEALTH (MEDS)?
What is the market cap of TRxADE HEALTH (MEDS)?
What is TRxADE Health, Inc.?
What services does TRxADE Health offer?
What is trxade.com?
What recent mergers has TRxADE Health completed?
What products are included in the recent acquisition by TRxADE Health?
How does TRxADE Health's platform benefit pharmaceutical buyers?
What is Superlatus, LLC?
What are pulse-based twisted protein snacks?
Where can I find products from TRxADE Health's acquired brands?
How does TRxADE Health contribute to the sustainable food sector?
